BioCentury | Aug 22, 2016
Company News

Sorrento deal

...on pain management. The separation is due to occur when Scintilla closes its acquisitions of Semnur Pharmaceuticals Inc....
...an NDA for ZTlido early next year. Following the Scilex deal, Scintilla agreed to acquire Semnur...
...million in cash, $20 million in Sorrento stock and up to $140 million in milestones. Semnur’s...
BioCentury | Aug 16, 2016
Company News

Sorrento planning pain spinout

...on pain management. The separation is due to occur when Scintilla closes its acquisitions of Semnur Pharmaceuticals Inc....
...acquire Semnur for $40 million in cash and $20 million in Sorrento shares up front. Semnur's...
...The company's investors included Frazier Healthcare Partners , Vivo Capital and Canaan Partners. Scintilla said Semnur's...
BioCentury | Oct 7, 2013
Finance

Lucky No. 7

...as part of a $6 million private round completed in August by back pain company Semnur Pharmaceuticals Inc....
Items per page:
1 - 3 of 3
BioCentury | Aug 22, 2016
Company News

Sorrento deal

...on pain management. The separation is due to occur when Scintilla closes its acquisitions of Semnur Pharmaceuticals Inc....
...an NDA for ZTlido early next year. Following the Scilex deal, Scintilla agreed to acquire Semnur...
...million in cash, $20 million in Sorrento stock and up to $140 million in milestones. Semnur’s...
BioCentury | Aug 16, 2016
Company News

Sorrento planning pain spinout

...on pain management. The separation is due to occur when Scintilla closes its acquisitions of Semnur Pharmaceuticals Inc....
...acquire Semnur for $40 million in cash and $20 million in Sorrento shares up front. Semnur's...
...The company's investors included Frazier Healthcare Partners , Vivo Capital and Canaan Partners. Scintilla said Semnur's...
BioCentury | Oct 7, 2013
Finance

Lucky No. 7

...as part of a $6 million private round completed in August by back pain company Semnur Pharmaceuticals Inc....
Items per page:
1 - 3 of 3